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ABSTRACT It has long been suspected that chronic
stress can exacerbate, or even cause, disease. We now
propose that the RCAN1 gene, which can generate
several RCAN1 protein isoforms, may be at least par-
tially responsible for this phenomenon. We review data
showing that RCAN1 proteins can be induced by mul-
tiple stresses, and present new data also implicating
psychosocial/emotional stress in RCAN1 induction. We
further show that transgenic mice overexpressing the
RCAN1–1L protein exhibit accumulation of hyperphos-
phorylated tau protein (AT8 antibody), an early precur-
sor to the formation of neurofibrillary tangles and
neurodegeneration of the kind seen in Alzheimer dis-
ease. We propose that, although transient induction of
the RCAN1 gene might protect cells against acute stress,
persistent stress may cause chronic RCAN1 overexpres-
sion, resulting in serious side effects. Chronically ele-
vated levels of RCAN1 proteins may promote or exac-
erbate various diseases, including tauopathies such as
Alzheimer disease. We propose that the mechanism by
which stress can lead to these diseases involves the
inhibition of calcineurin and the induction of
GSK-3 by RCAN1 proteins. Both inhibition of cal-
cineurin and induction of GSK-3 contribute to
accumulation of phosphorylated tau, formation of
neurofibrillary tangles, and eventual neurodegenera-
tion.—Ermak, G., Pritchard, M. A., Dronjak, S., Niu,
B., Davies, K. J. A. Do RCAN1 proteins link chronic
stress with neurodegeneration? FASEB J. 25, 3306–3311
(2011). www.fasebj.org
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The RCAN1 gene was originally discovered in the
mid-1990s (1, 2). The gene was “rediscovered” several
times, resulting in a confusing plethora of unrelated
names, including DSCR1, Adapt78, MCIP1, RCN1,
and others. In 2007, sufficient agreement was
achieved to rename the gene RCAN1 to reflect one of
its main functions: regulation of the serine/
threonine phosphatase, commonly known as cal-
cineurin (3). There is also evidence that RCAN1
proteins may have other important properties, in-
cluding regulating the mitochondrial ADP/ATP
translocator (ANT; ref. 4) and binding, and possibly
modulating the activity of, MAP3K kinase (5).
The RCAN1 gene consists of 7 exons, 3 of which
(exons 5, 6, and 7) appear to be invariant in all RCAN1
isoforms. The remaining 4 exons (exons 1–4) can be
alternatively spliced to produce a number of different
mRNA isoforms (6). In human brains, RCAN1 is ex-
pressed at the highest levels in neurons, and at least 3
RCAN1 proteins (RCAN1s) are expressed: 2 RCAN1–1s
(1–1L and 1–1S) and RCAN1–4 (3, 7). Of these three,
RCAN1–1L is the most abundant isoform in adult
human brain.
In addition to important roles in normal physiology,
RCAN1 proteins are also connected to tau protein
pathology and A pathology. On one hand, overexpres-
sion of RCAN1s can lead to accumulation of phosphor-
ylated tau (ref. 7 and more details below). On the other
hand, A, which is responsible for the formation of
amyloid plaques, can directly induce overexpression of
RCAN1s (8) that may, subsequently, lead to tau hyper-
phosphorylation and the formation of neurofibrillary
tangles. Thus, RCAN1s may explain why both amyloid
plaques and neurofibrillary tangles are formed in Alz-
heimer disease and Down syndrome. It is currently
accepted that the production of A, which then leads
to tau hyperphosphorylation, plays a causal role in both
diseases. In the current work, we review evidence and
provide new data to suggest that many types of stress,
including psychosocial/emotional stress, can cause
chronic RCAN1 overexpression. Thus, chronic stress
may contribute to accumulation of phosphorylated tau,
formation of neurofibrillary tangles, and eventual neu-
rodegeneration.
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RCAN1 GENE CAN BE INDUCED BY MULTIPLE
STRESSES
In our laboratory, RCAN1 (originally called Adapt78)
was discovered as a gene that is induced during tran-
sient adaptation to oxidative stress (1). It has, subse-
quently, become clear that RCAN1 is also induced by a
variety of other stresses. This is potentially very impor-
tant, because many human diseases are associated with,
or exacerbated by, increased stress. The fact that
RCAN1 can be induced biomechanically by traumatic
injuries is of particular interest in regard to neurode-
generation. For example, in vitro studies have demon-
strated direct biomechanical induction of RCAN1 in
cardiac myocytes (9). We have also observed similar
phenomena in cultured neuronal-like PC-12 cells, in
which RCAN1 can be induced by scraping adherently
grown cells (unpublished results).
Recent studies and new data suggest that RCAN1
gene expression may also be induced by psychological
stress. It has been shown that expression of RCAN1–1
mRNA, which encodes the RCAN1–1L and RCAN1–1S
proteins, is induced by glucocorticoids, but RCAN1–4
mRNA is not induced (10, 11). Interestingly, expres-
sion of RCAN1–1 mRNA was induced in the absence of
protein synthesis, indicating that it was induced directly
by glucocorticoids rather than through the synthesis of
signaling proteins or peptides. It is also important to
note that glucocorticoid levels can be increased by
biomechanical stress (12), suggesting that elevated
levels of RCAN1–1L and RCAN1–1S after biomechanical
stress may result from production of glucocorticoids.
Glucocorticoids carry out a number of important
functions, including adaptation to stressful conditions,
particularly, psychosocial/emotional stresses of the
kind with which most humans must contend in their
everyday lives. This, and the fact that RCAN1–1L is
the isoform predominantly expressed in human brain,
makes RCAN1–1L a particularly interesting protein for
further study in stress regulation and adaptation in
human brain, and in various brain diseases. Therefore,
we performed studies to address whether psychological
stress can actually lead to RCAN1–1L induction, using a
rat model. In these studies, rats were exposed either to
immobilization or isolation stress, and the levels of
RCAN1–1L were analyzed (Fig. 1). The efficacy of stress
was evaluated by measuring hormonal levels in plasma,
and all brain samples were obtained from previously
described animals (13). We analyzed the hippocampus,
since it contains high levels of glucocorticoid receptors,
which make it more vulnerable to long-term stress than
other parts of the brain (14, 15). Our results demon-
strate that RCAN1–1L levels approximately doubled in
rat hippocampus within 2 h after either isolation or
immobilization stress. Thus, it does appear that psycho-
social/emotional stress can induce RCAN1–1L. Simi-
larly, RCAN1–1S levels were also approximately dou-
bled after both stresses. However, levels of RCAN1–4
were not significantly elevated (data not shown). This
may be due to the fact that the RCAN1–1 and
RCAN1–4 isoforms are regulated by different promot-
ers: RCAN1–4 is regulated by the proximal promoter,
while both RCAN1–1s are regulated by the distal pro-
moter (3).
STRESS CAN CAUSE NEURODEGENERATION
A variety of stresses have been associated with neurode-
generation. For example, epidemiological studies sug-
gest that mechanical stress caused by head injury or
trauma (16, 17), or by contact sport exposures, such as
soccer (18) or boxing (19), can cause neurodegenera-
tive diseases. It has been estimated, for example, that
the risk of Alzheimer disease may be increased by as
Figure 1. RCAN1–1L levels are elevated in hippocampus of rats
exposed to immobilization or isolation stress. Adult rats were exposed
to stress. Eleven-week-old male Wistar rats were maintained and
manipulated as fully described in Gavrilovic et al. (13). All experiments
described were performed in accordance with the U.S. National
Institutes of Health Guide for the Care and Use of Laboratory Animals
(NIH publication 80-23). Animals were sacrificed at 2 h after stress was
terminated, and the hippocampus from the right hemisphere of each
brain was isolated for analysis. A) Example of Western blot analysis of RCAN1–1L expression; 5 control and 6 stressed
animals per group were analyzed. -Tubulin was used to control sample loading. B) Summary of Western analyses.
RCAN1–1L levels are reported in arbitrary units, which were set as follows: absorption of the first RCAN1–1L control
sample was set as 1.0 in the group of immobilized rats; absorption of the first control sample was set as 1.0 in the group
of isolated rats. All values were then adjusted according to the loading levels, as measured by -tubulin absorbance. All
values are shown as means  se. The experiments were repeated using 3-tubulin as the loading control, and we
obtained essentially identical results (confirmatory data not shown). In both the immobilized and isolated groups,
hippocampal RCAN1–1L levels were significantly increased (2.0-fold after immobilization stress and 1.7-fold after
isolation stress), as evaluated by Student’s t test (P0.05).
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much as 15% as a result of head trauma (20). Interest-
ingly, data indicating that psychological stress can also
cause neurodegeneration and Alzheimer disease have
been published. For example, it has been shown that
elderly individuals subjected to psychological stress are
more likely to develop Alzheimer disease than are
age-matched, nondistressed individuals (21). More-
over, it has been shown, using the Alzheimer disease
triple-transgenic mouse model, that chronic stress di-
minishes learning and memory, while increasing amy-
loid deposition (22), one of the hallmarks of Alzheimer
disease. It has been also demonstrated, using mouse
models, that stress can induce the accumulation of
phosphorylated tau (23–25). In turn, the accumulation
of phosphorylated tau can lead to the formation of
neurofibrillary tangles, another hallmark of Alzheimer
disease, and other forms of neurodegeneration.
RCAN1 GENE OVEREXPRESSION IS
ASSOCIATED WITH NEURODEGENERATION
It was observed that RCAN1 is overexpressed in Alzhei-
mer disease (8, 26, 27), which is characterized by
progressive neurodegeneration. Alzheimer disease be-
longs to a group of ailments called “tauopathies,” one
of the hallmarks of which is neurodegeneration that
involves the formation of neurofibrillary tangles due to
accumulation of hyperphosphorylated tau protein.
RCAN1 is also overexpressed in Down syndrome (8, 28,
29), and it should be noted that patients with Down
syndrome typically experience an early-onset and ag-
gressive form of Alzheimer disease. It has also been
found that both loss-of-function and overexpression of
the Drosophila ortholog of the RCAN1, called nebula,
leads to severe learning defects (30). Finally, it has been
reported that RCAN1 overexpression diminishes mito-
chondrial respiratory activity (MTT assay) in cultured
murine neurons (31), which would be expected to
cause neuronal damage.
MECHANISMS BY WHICH RCAN1 INDUCTION
MAY LEAD TO NEURODEGENERATION
One mechanism by which RCAN1 may harm neurons
might involve calcineurin, which dephosphorylates the
tau protein. The activity of calcineurin can be down-
regulated by RCAN1 proteins, and calcineurin activity
levels have been reported to decrease in Alzheimer
disease (32). Notably, the RCAN1 gene and calcineurin
are expressed at similar times, in similar regions of the
brain, and in similar (neuronal) cell types (8, 33, 34).
Calcineurin inhibition has been associated with tau
phosphorylation at threonine 181 and 231 (T181 and
T231). These same phosphorylated residues are seen in
paired helical filament preparations from Alzheimer
disease brains (35). Other investigations have shown
that calcineurin inhibitors cause tau phosphorylation
on both serine and threonine residues, both of which
are phosphorylated in Alzheimer disease (36). A sepa-
rate study reported that calcineurin inhibition pre-
vented the proteolysis of tau by calpain (37), and we
have also shown that calcineurin inhibition can de-
crease the degradation of tau by the proteasome (38).
Finally, it has also been demonstrated that elevated
levels of T181 and T231 tau, and total tau in the
cerebrospinal fluid, together constitute a biomarker
test with quite good accuracy for predicting incipient
Alzheimer disease (39).
Calcineurin may not, however, play a crucial role in
Alzheimer disease. It has been claimed, for example,
that other phosphatases, such as PP2A, might exert
more important effects (40). Therefore, the finding
that RCAN1s also induce GSK-3 synthesis (resulting in
increased tau phosphorylation) may be even more
interesting (8) because there is a general agreement
that activation of GSK-3 is an important factor in
Figure 2. Tau phosphorylation is increased in the hippocam-
pus of RCAN1 transgenic mice. Mice (CBA/Bl6 males) were
aged to 16 mo, and wild-type mice were compared to
transgenic mice that constitutively overexpress RCAN1–1L
(fully described in ref. 42). A) Representative photographs of
hippocampus from wild-type and RCAN1 transgenic mice
stained for the AT8 antibody. More darkly stained cells were
observed in sections from transgenic mice (arrows) compared
with controls. B) Summary of immunohistochemical analysis.
Hippocampal sections from 4 transgenic and 4 wild-type mice
were probed with AT8, AT100, and PHF6 antibodies; 8
sections/animal were analyzed. Sections were photographed
and signal intensities in whole fields were quantified using
ImageJ software (U.S. National Institutes of Health, Bethesda,
MD, USA). Results are means  se. Tau phosphorylation
levels were significantly (1.97-fold) increased in sections
stained with the AT8 antibody, as evaluated by Student’s t test
(P0.05).
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neurodegeneration and Alzheimer disease (reviewed in
refs. 40, 41). Induction of GSK-3 by RCAN1 was
discovered in PC-12 neuronal-like cells, and more stud-
ies using more relevant models would be extremely
helpful in properly exploring this phenomenon.
Regardless of whether RCAN1s operate mostly by
inhibition of calcineurin or by induction of GSK-3 (or
both), RCAN1–1L induction may lead to accumulation
of hyperphosphorylated tau, which is an important step
in the formation of neurofibrillary tangles. To begin to
test this hypothesis, we have now performed prelimi-
nary studies using an RCAN1-overexpressing transgenic
mouse that was recently described (42) as a model. In
this model, the isoform 1 splice variant, which encodes
the RCAN1–1L and RCAN1–1S proteins, was placed
under the control of the endogenous promoter to
mirror, as closely as possible, the situation in Down
syndrome and Alzheimer disease. Our data indicate
that hyperphosphorylated tau accumulates in hippocampal
neurons in mice overexpressing RCAN1–1L (Fig. 2).
This accumulation is only found using the AT8 anti-
body, which detects early stages of neurofibrillary tan-
gle formation, but not with AT100 or PFH6 antibodies,
which detect later stages of neurofibrillary tangle mat-
uration. These data indicate that the accumulation of
hyperphosphorylated tau, after RCAN1–1L overexpres-
sion, is a slow and gradual process, which corresponds
to the slow process (spanning many years) of tangle
formation in Alzheimer disease. It is estimated, for
example, that just the process of forming mature
neurofibrillary tangles from the pretangle stage may
take 20 yr (43). This is entirely consistent with the
observation that acute RCAN1 overexpression is protec-
tive against transient stress, with no expected negative
long-term effects on tau, because such side effects
would require years of chronic RCAN1 overexpression.
Similarly, since RCAN1 is chronically overexpressed in
the brains of patients affected by Down syndrome from
Figure 3. Possible mechanisms by which stress may cause neurodegenerative diseases via chronic RCAN1 induction. Multiple
forms of chronic stress can induce expression of RCAN1 proteins. Although both RCAN1–1 and RCAN1–4 protein levels are
induced by stress, the mechanisms of induction appear to be different: RCAN1–4 is induced by mRNA transcription
(transcriptional activation), whereas RCAN1–1 proteins seem to be induced by posttranscriptional mechanisms (translational
activation) (31, 44). Chronically elevated levels of RCAN1 proteins can inhibit calcineurin and activate GSK-3, both of which
can lead to the accumulation of hyperphosphorylated tau protein. The accumulation of hyperphosphorylated tau can
(eventually) cause the formation of neurofibrillary tangles, and lead to neurodegeneration.
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birth (8, 28, 29), this hypothesis is also consistent with
the fact that patients with Down syndrome typically
develop neurofibrillary tangles and experience onset of
Alzheimer disease at 40 yr of age.
In summary, we propose that stress can cause neuro-
degeneration by inducing RCAN1 gene overexpression.
While transient induction of RCAN1 (e.g., transient
oxidative stress), typically lasts for just a few hours and
can protect cells against stresses, chronic overexpres-
sion will cause serious side effects and cell damage. At
least one such side effect seems to be increased phos-
phorylation of the tau protein, which may result both
from induction of GSK-3 and from inhibition of
calcineurin. The consequent accumulation of phos-
phorylated tau may ultimately lead to the formation of
neurofibrillary tangles, which then contribute to the
neurodegenerative process observed in many tauopa-
thies (Fig. 3).
Finally, it is noteworthy that RCAN1–1L production
can be also induced by glucocorticoids. Expression of
glucocorticoids is induced by several stresses, including
psychosocial/emotional stresses of the kind we experi-
ence in everyday life. Since exposure to glucocorticoids
can induce the accumulation of phosphorylated tau
(23–25), it is possible that mechanisms by which psy-
chological stress contributes to neuronal damage might
also involve RCAN1s: i.e., chronic psychosocial/emo-
tional stress induces chronic production of glucocorti-
coids, which then cause overexpression of RCAN1–1L,
leading to accumulation of phosphorylated tau and
eventual cell degeneration (Fig. 3). It has long been
suspected that emotional and psychological stresses can
cause neurodegeneration. We now propose that
RCAN1 proteins may be at least a partial explanation
for this phenomenon.
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